Psychotic Disorders - Czechia | Statista Market Forecast

Revenue in the Psychotic Disorders market is projected to reach US$10.10m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of -3.31%, resulting in a market volume of US$8.54m by 2029.
In global comparison, most revenue will be generated United States (US$2.26bn in 2024).
In relation to total population figures, per person revenues of US$105.70 are generated in 2024.

Psychotic disorders are severe mental health disorders that cause changes in a person's way of thinking and their perception. Patients often have trouble differentiating between what they perceive and reality. Different types of psychotic disorders include schizophrenia, bipolar disorder, substance-induced psychotic disorder, delusional disorder, and brief psychotic disorder. However, this market only represents the sales of antipsychotic drugs that are used to treat schizophrenia and bipolar disorder.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, Recordati S.p.A., Gadeon Richter, Sumitomo Pharma, Johnson & Johnson / Janssen, Vanda Pharmaceuticals, Alkermes, Eli Lilly, AstraZeneca, and Intra-Cellular Therapies

Antipsychotic drugs: Aripiprazole (Abilify), Asenapine (Saphris), Cariprazine (Vraylar), Clozapine (Clozaril, Versacloz), lumateperone (Caplyta), Lurasidone (Latuda), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Risperidone (Aristada), Ziprasidone (Geodon), Brexpiprazole (Rexulti), Iloperidone (Fanapt), and Paliperidone (Invega)

Psychotherapy
Talk therapy
Herbal medicines
Digital health apps
Deep Brain Stimulation (DBS)

The Psychotic Disorders market in Czechia is experiencing steady growth driven by customer preferences for innovative treatment options, increasing awareness about mental health, and favorable government initiatives.

Customer preferences: Customers in Czechia are increasingly seeking innovative and personalized treatment options for psychotic disorders. They are looking for therapies that not only alleviate symptoms but also improve their overall quality of life. As a result, there is a growing demand for novel medications with fewer side effects and better efficacy. Additionally, customers are also showing interest in non-pharmacological interventions such as cognitive-behavioral therapy and psychosocial support programs.

Trends in the market: One of the key trends in the Psychotic Disorders market in Czechia is the rising awareness about mental health. The stigma associated with mental illnesses is gradually diminishing, leading to increased acceptance and openness in seeking treatment. This has resulted in a higher number of patients being diagnosed with psychotic disorders and seeking appropriate medical care.Another trend in the market is the implementation of government initiatives aimed at improving mental health services. The Czech government has been actively investing in mental health infrastructure, including the establishment of specialized psychiatric hospitals and outpatient clinics. This has not only improved access to care but also enhanced the quality of treatment options available for patients with psychotic disorders.

Local special circumstances: Czechia has a well-developed healthcare system that provides universal coverage to its citizens. This ensures that individuals with psychotic disorders have access to necessary medical care without financial barriers. The country also has a strong network of mental health professionals, including psychiatrists and psychologists, who play a crucial role in diagnosing and treating patients with psychotic disorders.

Underlying macroeconomic factors: The growth of the Psychotic Disorders market in Czechia is also influenced by several macroeconomic factors. The country has experienced steady economic growth in recent years, leading to increased healthcare spending. This has allowed for the development and adoption of new and advanced treatment options for psychotic disorders.Furthermore, the aging population in Czechia is contributing to the growth of the market. As the population ages, the prevalence of mental health disorders, including psychotic disorders, is expected to increase. This demographic shift is driving the demand for effective and specialized treatments for this patient group.In conclusion, the Psychotic Disorders market in Czechia is witnessing growth due to customer preferences for innovative treatment options, increasing awareness about mental health, and favorable government initiatives. The market is expected to continue expanding as the country invests in mental health infrastructure and the demand for personalized and effective therapies for psychotic disorders continues to rise.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.